Fig. 5: NFAT5 promotes FR expression phenotype in cultured RPTECs.

a Expression of NFAT5 and VCAM1 in cultured RPTECs treated with (n = 3 independent samples) non-targeting (NT) or (n = 3 independent samples) NFAT5-targeting small interfering RNA (siRNA). RNA levels measured by quantitative reverse transcription PCR (RT-qPCR) and normalized to GAPDH expression. NFAT5 siRNA-treated cells had 22% of the NFAT5 RNA and 57% of the VCAM1 RNA levels of non-targeting-siRNA-treated cells. P values calculated with two-tailed t-test with unequal variance. Data are presented as mean ± standard deviation. Source data are provided in the Source Data file. b Heatmap of select differentially expressed genes by RNA-seq in NT and NFAT5 siRNA-treated RPTECs. c Number of predicted NFAT5 targets by each method, separated into target genes that were bound versus unbound on NFAT5 CUT&RUN-seq performed on n = 2 independent RPTEC samples. 379/445 RENIN-predicted targets, 104/116 Pando-predicted targets, 53/67 CellOracle-predicted targets, 274/305 SCENIC + -predicted targets, and 31/40 FigR-predicted targets were bound by NFAT5 assessed by CUT&RUN-seq on RPTEC culture. d Distal predicted CRE for TPM1, predicted to be NFAT5 target FR gene and downregulated with siRNA NFAT5 knockdown, bound by NFAT5. e Immunofluorescent labeling of NFAT5 in adult human kidney. DAPI is a nucleus marker and LTL is an apical proximal tubule marker. * denotes examples of tubules with low LTL intensity. Representative image of n = 3 independently analyzed samples. Sample clinical data in Source Data. Scale bars are 50 µm in length.